A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.
In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.
advertisement
Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds
Next article： Psychedelics group wrestles with new pharma identity
Next article： Psychedelics group wrestles with new pharma identity
